CLXPF News and Press, Canadian Lynx Pete Ltd From 06/11/21

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the H.C. Wainwrig...

Cybin submits first-ever Patent Cooperation Treaty (“PCT”) filing By filing a single PCT application, the company simultaneously seeks protection for its proprietary drug treatments in a large number of countries Cybin filed the PCT application to provide broad inte...

Unlike other hard drugs, hallucinogens such as LSD are seen as less likely to give rise to physical dependence and as less harmful. However, they are hardly safe, and sometimes their use is followed by unpredictable and intense psychological dependency, flashbacks and cognitive impairment....

Palm Beach, FL – June 8, 2021 – The illegal drugs of the 1960’s are becoming highly valued drugs for various new therapeutic uses across a growing list of maladies. The door of previously prohibited drugs has been opening and it appears that there will be more treatment...

-- EMBARK is a ground-breaking psychotherapy model that integrates leading clinical approaches to promote supportive healing with psychedelic medicine -- Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechno...

Cybin (NEO: CYBN) (OTCQB: CLXPF) CEO Doug Drysdale will be participating at the 2021 LD Micro Invitational XI. The invitational will be held Thursday, June 10. As part of his participation, Drysdale will be presenting a live webcast featuring Cybin, a biotechnology company focused on progr...

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF), a biotechnology company focused on progressing psychedelic therapeutics, today announced that Doug Drysdale, Chief Executive Officer, will be presenting at the 2021 LD Micro Invitational XI. The presentation details are as follows: The ...

Psychedelics such as LSD, MDMA, ayahuasca and psilocybin have become popular in the last few years as researchers discover more about the substances and the therapeutic benefits they possess. While these substances have been a part of the popular culture in the West for some decades now, o...

Cybin (NEO: CYBN) (OTCQB: CLXPF) , a biotechnology company focused on progressing psychedelic therapeutics, today announced the sponsorship of Kernel’s feasibility study of its Kernel Flow technology to measure ketamine’s psychedelic effect on cerebral cortex hemodynamics. In ...

Cybin Inc. ( NEO:CYBN ) (OTCQB:CLXPF) (“ Cybin ” or the “ Company ”), a biotechnology company focused on progressing psychedelic therapeutics, today announced the sponsorship of Kernel’s feasibility study of its Kernel Flow technology t...